Charles M. Perou

TL;DR: A signaling mechanism through which stem and mesenchymal states are acquired in mammary cells is demonstrated and therapeutic avenues in breast cancers for which targeted therapies are currently unavailable are suggested.

TL;DR: The CbD regimen was well tolerated and yielded high pCR rates in both BRCA-associated and wild-type TNBC, comparable with pCR achieved with the addition of carboplatin to anthracycline–taxane chemotherapy.

TL;DR: SFRP2 is a novel stimulator ofAngiogenesis that stimulates angiogenesis via a calcineurin/NFAT pathway and may be a favorable target for the inhibition of angiogenic in solid tumors.

TL;DR: How by understanding this circuit and its vulnerabilities, it may be possible to identify novel therapy for TNBC and to connect Rb and p53 to EMT in TNBC is discussed.

TL;DR: The causal role of EZH2 overexpression in NSCLC is demonstrated with new genetically engineered mouse models of lung adenocarcinoma, and a potent open-source EZh2 inhibitor, JQEZ5, is developed that promotes regression of EzH2-driven tumors in vivo, revealing a potential role for anti-EZH1 therapy in lung cancer and providing the rationale for epigenetic therapy in a subset of lung cancer.